Alzheimer's Disease/Cognition News

In patients with type 2 diabetes, semaglutide was associated with a significantly lower risk for an Alzheimer’s disease diagnosis within 3 years compared with other diabetes medications, according to a study published in Alzheimer’s & Dementia.

BOSTON — In this Healio video exclusive, Virend K. Somers, MD, PhD, discusses his presentation at the Cardiometabolic Health Congress, “Sleep Disorders and Cardiometabolic Health.”

A genetic analysis of postmortem brains from individuals in various stages of Alzheimer’s disease revealed two distinct phases of cell deterioration, according to research published in Nature Neuroscience.

Results from a clinical trial examining intracranial stimulation using a novel device in those with mild Alzheimer’s disease showed that treatment led to improvements in memory, cognitive function and blood flow.

Women with breast cancer who began an aerobic exercise program at the start of chemotherapy self-reported improved cognitive function and quality of life, according to results of a randomized trial.

The NIH has awarded a $3.3 million grant to advance a novel, oral silent allosteric modulator intended to treat Alzheimer’s and Parkinson’s diseases, according to the manufacturer.

Falling was associated with an increased risk for a diagnosis of Alzheimer’s disease or other dementias in older adults, according to a recent analysis in JAMA Network Open.

The world is facing an impending tsunami as the number of people developing Alzheimer’s disease continues to grow.

Older adults diagnosed with a blood cancer exhibited similar rates of cognitive decline as cancer-free controls, according to study results.

A New York-based biotechnology company has received a $4 million grant from the NIH’s National Institute on Aging to advance a novel intranasal therapeutic to treat Alzheimer’s disease, according to a press release from the manufacturer.